Home Multicancer early detection
Article
Licensed
Unlicensed Requires Authentication

Multicancer early detection

  • Eric A. Klein ORCID logo EMAIL logo , Tomasz M. Beer and Michael Seiden
Published/Copyright: February 3, 2022

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Lot-to-lot variation: no longer a neglected issue
  4. Review
  5. Health Technology Assessment to assess value of biomarkers in the decision-making process
  6. Mini Review
  7. Diagnostic performance of the fully automated Roche Elecsys SARS-CoV-2 antigen electrochemiluminescence immunoassay: a pooled analysis
  8. Opinion Papers
  9. Preanalytical quality improvement – an interdisciplinary journey
  10. Metrological traceability and clinical traceability of laboratory results – the role of commutability in External Quality Assurance
  11. Lot-to-lot reagent verification: challenges and possible solutions
  12. EFLM Paper
  13. An approach for determining allowable between reagent lot variation
  14. General Clinical Chemistry and Laboratory Medicine
  15. Introduction of BD Vacutainer® Barricor™ tubes in clinical biobanking and application of amino acid and cytokine quality indicators to Barricor plasma
  16. Delays during PBMC isolation have a moderate effect on yield, but severly compromise cell viability
  17. Investigation of the effects of pneumatic tube transport system on routine biochemistry, hematology, and coagulation tests in Ankara City Hospital
  18. Comparison of three different protocols for obtaining hemolysis
  19. Report from the HarmoSter study: impact of calibration on comparability of LC-MS/MS measurement of circulating cortisol, 17OH-progesterone and aldosterone
  20. Point-of-care testing in primary healthcare: a scoring system to determine the frequency of performing internal quality control
  21. Hematology and Coagulation
  22. The flagging features of the Sysmex XN-10 analyser for detecting platelet clumps and the impacts of platelet clumps on complete blood count parameters
  23. Cancer Diagnostics
  24. Thyroglobulin and thyroglobulin antibodies: assay-dependent management consequences in patients with differentiated thyroid carcinoma
  25. Infectious Diseases
  26. Hyris bCUBE SARS-CoV-2 rapid molecular saliva testing: a POCT innovation on its way
  27. Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection
  28. Identification of contagious SARS-CoV-2 infected individuals by Roche’s Rapid Antigen Test
  29. Monocyte distribution width (MDW) as a screening tool for early detecting sepsis: a systematic review and meta-analysis
  30. Perinatal asphyxia partly affects presepsin urine levels in non-infected term infants
  31. Letters to the Editors
  32. Spurious results for total and free prostate-specific antigen (PSA); sometimes really “a riddle wrapped in a mystery inside an enigma”
  33. Reply to: Spurious results for total and free prostate-specific antigen (PSA); sometimes really “a riddle wrapped in a mystery inside an enigma”
  34. Spike vs. nucleocapsid serum antigens for COVID-19 diagnosis and severity assessment
  35. A rapid semi-quantitative test for determination of SARS-CoV-2 antibody levels
  36. Diagnostic potential of leukocyte differential and cell population data in prediction of COVID-19 among related viral and bacterial infections at Emergency Department
  37. Added value of drug-laboratory test interaction alerts in test result authorisation
  38. Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma
  39. Rare unstable and low oxygen affinity haemoglobin variant, Hb Hazebrouck, detected on Sysmex XN-9000
  40. Multicancer early detection
Downloaded on 28.5.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2022-0058/html
Scroll to top button